Scarica l'app Stockscreener
219.58
0.17%
-0.37
Dopo l'orario di chiusura:
219.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$219.95
Aprire:
$217.93
Volume 24 ore:
826.59K
Relative Volume:
0.58
Capitalizzazione di mercato:
$31.67B
Reddito:
$5.54B
Utile/perdita netta:
$1.52B
Rapporto P/E:
21.17
EPS:
10.3734
Flusso di cassa netto:
$1.74B
1 W Prestazione:
-4.19%
1M Prestazione:
-0.21%
6M Prestazione:
-11.14%
1 anno Prestazione:
-18.82%
Intervallo 1D:
$215.80
$221.25
Intervallo di 1 settimana:
$215.80
$228.49
Portata 52W:
$180.26
$284.87
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
219.58 | 31.73B | 5.54B | 1.52B | 1.74B | 10.37 |
ISRG
Intuitive Surgical Inc
|
360.46 | 124.79B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
176.42 | 48.98B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
66.55 | 33.08B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
32.39 | 29.87B | 29.14B | 1.07B | 1.05B | 1.1956 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | JP Morgan | Overweight |
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
ResMed Inc. stock dips as CEO share sale draws investor attention - ad-hoc-news.de
ResMed: A Significant Upside Despite The Perceived Risk (NYSE:RMD) - Seeking Alpha
ResMed CEO Michael Farrell sells $1.11 million of company shares By Investing.com - Investing.com India
ResMed (NYSE:RMD) CEO Michael Farrell Sells 4,991 Shares - MarketBeat
Are Resmed CDI (ASX:RMD) shares good value in 2026? - Rask Media
Citigroup Adjusts Price Target on ResMed to $240 From $235, Keeps Neutral Rating - marketscreener.com
Amundi Trims Holdings in ResMed Inc. $RMD - MarketBeat
ResMed stock heads into the open after a 3.3 percent slide - ad-hoc-news.de
Will ResMed Sleep Research Sharpen Its Case (ASX:RMD)? - Kalkine Media
ResMed Inc. stock falls after valuation warning but fundamentals stay solid - ad-hoc-news.de
ResMed Inc. $RMD Shares Purchased by California State Teachers Retirement System - MarketBeat
ResMed (ASX:RMD) Shares Retreat While FY26 Growth Remains in Focus - Kalkine
Resmed Inc Draws Eyes to Healthcare Pathway (ASX:RMD) - Kalkine Media
Is ResMed Inc (RMD) a Bargain After 3.2% Drop? GF Value Says Und - GuruFocus
ResMed Inc. stock falls Tuesday, underperforms market - MarketWatch
Farrell Peter C Disposes of 970 Shares in ResMed at $234.73 Each on September 2, 2026 - Kalkine Media
ResMed Inc. stock slips as Astral halt and GLP-1 worries weigh on sentiment - ad-hoc-news.de
Insider at ResMed (NYSE: RMD) lines up a million-dollar stock sale - Stock Titan
Resmed Inc Stock (RMD) Moved Down by 3.15% on Sep 8: What Investors Need To Know - TradingKey
Saudi Central Bank Increases Position in ResMed Inc. $RMD - MarketBeat
Wellington Management Group LLP Grows Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Purchased by Hsbc Holdings PLC - MarketBeat
ResMed Inc. stock heads into the open after a 0.4% dip - ad-hoc-news.de
Why Is ResMed Inc. (ASX:RMD) Drawing Fresh Attention Among Healthcare Stocks? - Kalkine Media
How is ResMed (ASX:RMD) framing its sleep research push? - Kalkine Media
ResMed Inc. stock gains on FY2026 growth and buyback launch - ad-hoc-news.de
ResMed Inc Reports August 2026 CHESS Depositary Interests and Securities Update - Kalkine Media
Paralel Advisors LLC Purchases Shares of 10,293 ResMed Inc. $RMD - MarketBeat
ResMed Inc. (RMD) Stock Analysis: Navigating a 7.78% Upside Potential in the Healthcare Sector - directorstalkinterviews.com
ResMed Inc. $RMD Shares Acquired by Giverny Capital Inc. - MarketBeat
ResMed Inc Discloses August 2026 CDI and Securities Statement - Kalkine
Why Is ResMed (ASX:RMD) Sustaining Home-Care Demand? - Kalkine Media
ResMed Director Peter Farrell Sells 970 Shares Under Rule 10b5-1 Plan - Kalkine
ResMed Inc. stock holds above support as fiscal 2026 growth and cautious 2027 outlook shape sentimen - AD HOC NEWS
ResMed Director Peter Farrell Executes Sale of 970 Shares via 10b5-1 Trading Plan - Kalkine Media
ResMed chairman emeritus Peter Farrell sells $227,688 in stock By Investing.com - Investing.com South Africa
ResMed (NYSE:RMD) Director Peter Farrell Sells 970 Shares - MarketBeat
ResMed chairman emeritus Peter Farrell sells $227,688 in stock - Investing.com
ResMed (RMD) director sells shares under trading plan - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc.RMD - PR Newswire
Morgan Stanley Adjusts Price Target on ResMed to $225 From $227, Keeps Equalweight Rating - marketscreener.com
Nykredit A S Acquires New Position in ResMed Inc. $RMD - MarketBeat
ResMed (NYSE:RMD): A Quality Dividend Play Built on Sustainable Payouts - ChartMill
Jupiter Topco LLC Takes Position in ResMed Inc. $RMD - MarketBeat
Director at ResMed (NYSE: RMD) plans new 970-share stock sale - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 9,064 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by Van ECK Associates Corp - MarketBeat
ResMed (RMD) Announces $450 Million Accelerated Share Repurchase Agreement - GuruFocus
ResMed Enters $450 Million Accelerated Share Repurchase Agreement With Citibank; Shares Fall 3% - Moomoo
Is ResMed Inc (RMD) a Bargain After 3.6% Drop? GF Value Says Und - GuruFocus
ResMed Launches $450 Million Accelerated Share Buyback With Citibank - marketscreener.com
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.75%
2.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):